Overview

Allogeneic Gammadelta T Cells Combined With Interferon-α1b or PD-1 Monoclonal Antibody in Stage III-IV Amenable to Surgical Resection Melanoma

Status:
NOT_YET_RECRUITING

Trial end date:
2028-10-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of allogeneic γδ T cells combined with recombinant human interferon-α1b (IFN-α1b) or PD-1 monoclonal antibody in neoadjuvant treatment of patients with Stage III-IV resectable melanoma.

Phase:

EARLY_PHASE1

Details

Lead Sponsor:

Xijing Hospital

Collaborator:

Beijing GD Initiative Cell Therapy Technology Co., Ltd.

Treatments:

pembrolizumab